MIRA
INFORM REPORT
|
Report Date : |
04.02.2008 |
IDENTIFICATION
DETAILS
|
Name : |
TRANSASIA BIO-MEDICALS LIMITED |
|
|
|
|
Formerly Known As : |
TRANSASIA BIO-MEDICALS PRIVATE LIMITED |
|
|
|
|
Registered Office : |
Transasia House, Plat No.N-8, Chandivali Studio Road, Andheri (E) Mumbai – 400072, Maharashtra |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2007 |
|
|
|
|
Date of Incorporation : |
10.05.1985 |
|
|
|
|
Com. Reg. No.: |
036198 |
|
|
|
|
CIN No.: [Company
Identification No.] |
L33110MH1985PLC036198 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
MUMT00342G MUMT09181E |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACT2028C |
|
|
|
|
Legal Form : |
Public Limited Liability Company. The Company’s Share are listed on
the stock exchanges. |
|
|
|
|
Line of Business : |
Manufacturing, Marketing, Importers and Exporters of Instruments for measuring, Checking, Testing and Navigating. |
RATING &
COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 5476724 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established company having fine track records. Directors are reported as experienced, respectable and resourceful industrialists. Their trade relations are fair. Payments are correct and as per commitments. The company can be considered good for any normal business dealings. It can be regarded as a promising business partner in a medium to long run. Ms. Mary, Executive Secretary of the company conformed that they do have their own R and D Design Centre located at Transasia House. |
LOCATIONS
|
Registered Office : |
Transasia House, Plat No.N-8, Chandivali Studio Road, Andheri (E) Mumbai – 400072, Maharashtra, India |
|
Tel. No.: |
91-22-40309000/2857 5050 / 4040 |
|
Fax No.: |
91-22-2857 3030 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory 1 : |
47, Gelwad Falia, Dabhel, Opp. Somnath Bus Stop, Nani Daman – 396 210, Daman, Union Territory |
|
|
|
|
Factory 2 : |
B/11, GIDC, Ringanawada, Nani Daman – 396 210, Daman,
Union Territory |
|
|
|
|
Branches : |
Tel. No.: 91-11-2573 2223
Tel. No.: 91-44-2826 0310
Tel. No.: 91-33-2536 1458
Tel. No.: 91-79-2658 9140 |
|
|
|
|
Sales and Services office : |
|
DIRECTORS
|
Name : |
Mr. Suresh Hassanand Vazirani |
|
Designation : |
Chairman and
Managing Director |
|
Address : |
Flat No. 3 C. Mittal
Paradise, Opp. Mittal Park, Near Army Club, off J. Mhatre Marg, Juhu Beach,
Mumbai – 400049, Maharashtra, India |
|
Date of Birth/Age : |
15.07.1949 |
|
Experience : |
21 years |
|
Date of Appointment : |
10.05.1985 |
|
Email : |
|
|
|
|
|
Name : |
Mrs. Mala S.
Vazirani |
|
Designation : |
Director |
|
Address : |
Flat No. 3 C.
Mittal Paradise, Opp. Mittal Park, Near Army Club, off J. Mhatre Marg, Juhu Beach,
Mumbai – 400049, Maharashtra, India |
|
Date of Birth/Age : |
13.08.1958 |
|
Date of Appointment : |
01.12.1986 |
|
Email : |
|
|
|
|
|
Name : |
Mr. Francis
Mathew |
|
Designation : |
Director |
|
Address : |
209-D, Sheetal
Seven Bunglows, Andheri (West), Mumbai 400 058, Maharashtra, India |
|
Date of Birth/Age : |
10.07.1952 |
|
Date of Appointment : |
01.12.1986 |
|
Email : |
KEY EXECUTIVES
|
Name : |
Mr. Ravindra Baburao Yevle |
|
Designation : |
Company Secretary |
|
Address : |
C/O. Transasia House 8, Chandivali Studio Road, Andheri (E)
Mumbai – 400072, Maharashtra, India |
|
Date of Birth/Age : |
08.04.1954 |
|
Date of Appointment : |
26.04.2004 |
|
Email : |
MAJOR SHAREHOLDERS
/ SHAREHOLDING PATTERN
|
Names of Shareholders |
|
No. of Share |
|
|
|
|
|
Mr. Suresh H. Vazirani |
|
1359225 |
|
Mrs. Mala S. Vazirani |
|
640725 |
|
Mr. Luthria N. Vasudeo |
|
10 |
|
Mr. Francis
Mathew |
|
10 |
|
Mr. Vijay Parikh |
|
10 |
|
Mr. Chandu P. Sadarangani |
|
10 |
|
Mr. Sunil H. Vazirani |
|
10 |
|
|
|
|
|
Total |
|
2000000 |
|
|
|
|
|
Category |
|
Percentage |
|
|
|
|
|
Directors or relatives of directors |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing, Marketing, Importers and Exporters of Instruments for measuring, Checking, Testing and Navigating. |
|
|
|
|
Products : |
|
|
|
|
|
Exports : |
|
|
Countries : |
|
|
|
|
|
Imports : |
|
|
Countries : |
|
PRODUCTION STATUS
|
Particulars |
Unit |
Installed
Capacity |
Actual
Production |
|
|
|
|
|
|
Semi Auto Analyser |
|
1200 |
640 |
|
Auto Analyser |
|
250 |
88 |
|
Reagents |
|
0.500 Million (UOM: Ltrs.) |
0.350 Million (UOM: Ltrs.) |
GENERAL
INFORMATION
|
Customers : |
|
||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||
|
No. of Employees : |
350 |
||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||
|
Bankers : |
103/104 A- Wing 1
Floor, Deck Plaza, MIDC Central Road, Andheri (E), Mumbai – 400093,
Maharashtra, India
ICICI Towers, Bandra Kurla Complex, Bandra (E), Mumbai – 400051, Maharashtra, India |
||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
|
|
Name : |
Chandulal M. Shah and Company Chartered Accountants |
|
Address : |
304, Maker Bhavan No.3, 21, New Marine Lines, Mumbai – 400 020, Maharashtra, INDIA |
|
|
|
|
Associates/Subsidiaries : |
ERBA Diagnostics Mannheim GMBH |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
2000000 |
Equity Shares |
Rs.10/- each |
Rs.20.000 millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
2000000 |
Equity Shares |
Rs.10/- each |
Rs.20.000 millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
20.000 |
20.000 |
20.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1349.181 |
927.157 |
608.094 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
1369.181 |
947.157 |
628.094 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
0.000 |
0.000 |
2.093 |
|
|
2] Unsecured Loans |
92.603 |
36.314 |
14.221 |
|
|
TOTAL BORROWING |
92.603 |
36.314 |
16.312 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
1461.784 |
983.471 |
644.407 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
143.243 |
133.247 |
132.175 |
|
|
Capital work-in-progress |
0.000 |
19.077 |
7.034 |
|
|
|
|
|
|
|
|
INVESTMENT |
538.777 |
254.234 |
3.998 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
312.190
|
235.874 |
149.958 |
|
|
Sundry Debtors |
593.812
|
478.626 |
372.370 |
|
|
Cash & Bank Balances |
35.353
|
22.783 |
49.171 |
|
|
Other Current Assets |
56.669
|
48.672 |
47.701 |
|
|
Loans & Advances |
166.533
|
101.574 |
88.482 |
|
Total
Current Assets |
1164.557
|
887.529 |
707.682 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
259.015
|
207.119 |
131.944 |
|
|
Provisions |
125.778
|
103.883 |
75.032 |
|
Total
Current Liabilities |
384.793
|
311.002 |
206.976 |
|
|
Net Current Assets |
779.764
|
576.527 |
500.706 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.386 |
0.494 |
|
|
|
|
|
|
|
|
TOTAL |
1461.784 |
983.471 |
644.407 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
|
Sales Turnover |
1457.152 |
1235.371 |
915.968 |
|
|
Other Income |
45.303 |
21.559 |
8.969 |
|
|
Total Income |
1502.455 |
1256.930 |
924.937 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
515.808 |
391.340 |
224.074 |
|
|
Provision for Taxation |
58.663 |
37.604 |
16.322 |
|
|
Profit/(Loss) After Tax |
457.145 |
353.736 |
207.752 |
|
|
|
|
|
|
|
|
Export Value |
326.194 |
317.013 |
180.437 |
|
|
|
|
|
|
|
|
Import Value |
N.A. |
N.A. |
N.A. |
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Raw Material Consumed |
336.148 |
283.006 |
44.129 |
|
|
Purchases made for re-sale |
357.005 |
300.483 |
92.893 |
|
|
Consumption of stores and spares parts |
0.000 |
0.000 |
0.000 |
|
|
Increase/(Decrease) in Finished Goods |
(64.416) |
(41.703) |
0.000 |
|
|
Salaries, Wages, Bonus, etc. |
169.663 |
128.890 |
73.472 |
|
|
Managerial Remuneration |
0.000 |
0.000 |
0.000 |
|
|
Payment to Auditors |
0.168 |
0.165 |
26.620 |
|
|
Interest |
5.695 |
5.387 |
6.666 |
|
|
Insurance Expenses |
4.447 |
3.784 |
42.566 |
|
|
Power & Fuel |
0.000 |
0.000 |
0.000 |
|
|
Depreciation & Amortization |
19.616 |
18.341 |
0.465 |
|
|
Other Expenditure |
158.322 |
167.237 |
414.052 |
|
Total Expenditure |
986.648 |
865.590 |
700.863 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2007 |
31.03.2006 |
31.03.2005 |
|
PAT / Total Income |
(%) |
30.43
|
28.14 |
22.46 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
34.40
|
31.68 |
24.46 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
39.44
|
38.34 |
66.07 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.38
|
0.41 |
0.36 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
0.35
|
0.37 |
0.35 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
3.03
|
2.85 |
3.42 |
LOCAL AGENCY
FURTHER INFORMATION
Form 8 :
|
Corporate
identity number (CIN) Foreign company registration number |
L33110MH1985PLC036198 |
|
Name of the
Company |
TRANSASIA BIO-MEDICALS LIMITED |
|
Address |
Transasia House, Plat No.N-8, Chandivali Studio Road, Andheri (E) Mumbai – 400072, Maharashtra, India |
|
This form is for |
Creation of
Charge |
|
Type of Charge |
Book Debts Movable Property
(Not being pledge) Floating Charge Current Assets,
Movable Fixed Assets and P and M |
|
Particulars of
the charge holder |
ING Vysya Bank
Limited 103/104 A- Wing 1
Floor, Deck Plaza, MIDC Central Road, Andheri (E), Mumbai – 400093,
Maharashtra, India |
|
Nature or
description of the instrument(s) creating or modifying the charge |
General Hypothecation
Agreement dated 31st August, 2007 |
|
Date of the
instrument creating or modifying the charge |
31.08.2007 |
|
Amount secured by
the charge |
Rs.40.000
Millions |
|
Brief particulars
of the principal terms and conditions and extent and operation of the charge |
Rate of Interest
: CC : IVRR-4.00%
p.a. PCL/PSL (Sub
limit of CC) : IVRR-4.00% p.a. PCFC/EBRD (Sub
limit of CC) : LIBOR+100bps ILC/FLC (Sub
limit of CC) : Commission : As per bank norms BG (Sub limit of
CC) : Commission Up to 1 year – 0.60%>1year Upto 3 year – 0.75 (As Specifically
Mentioned in the general Hypothecation Agreement Dated 31.08.2007) Terms of
Repayment : CC : On Demand PCL/PSL (Sub
limit of CC) : On demand PCFC/EBRD (Sub
limit of CC) : On demand ILC/FLC (Sub
limit of CC) : On demand BG (Sub limit of
CC) : On demand (As Specifically
Mentioned in the general Hypothecation Agreement Dated 31.08.2007) Margin : CC : 25% on
inventory and receivables PCL/ PCFC/AACB (Sub
limit of CC) : 10% PSL/ EBRD (Sub
limit of CC) : Nil ILC/FLC (Sub
limit of CC) : 10% BG (Sub limit of
CC) : Nil (As Specifically
Mentioned in the general Hypothecation Agreement Dated 31.08.2007) Extent and
operation of the charge : First ranking pari
passu charge on entire current assets such as raw materials, stock in
process, finished goods, packing materials, spares and stores and book debts
etc. along with other multiple bankers. First ranking
pari passu charge on all movable fixed assets of the company, both present
and future along with other multiple bankers. First ranking
pari passu charge on entire plant and machinery both present and future along
with other multiple bankers. (As specified in
general hypothecation Agreement Dated 31.08.2007) |
|
Short particulars
of the property charged (including location of the property) |
Entire current
assets (Such as raw materials, stock in process, finished goods, packing
materials, spares and stores) all movable fixed assets entire plant and
machinery of the company from time to time stored at;
And Book debts of the company (As specified in
general hypothecation Agreement Dated 31.08.2007) |
|
Particular of the
present modification |
N.A. |
|
Name of the company |
TRANSASIA BIO-MEDICALS LIMITED |
|
Presented By |
Mr. Suresh
Vazirani – Director Mrs. Mala
Vazirani – Director |
|
1) Date and description of instrument creating the change |
Deed Hypothecation dated the 28th day of March, 2001. executed by TRANSASIA BIO-MEDICALS LIMITED, (therein and hereafter referred to as the company )In favour of ICICI Limited (therein and Hereafter referred to as ICICI). |
|
2) Amount secured by the charge/amount owing on the securities of charge |
Term Loan Rs.50.000
Millions (therein and hereafter referred to as the facility) |
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
The Whole of the movable properties of the borrower including its movable plant and machinery, machinery spares, tools and accessories and other movables, both present and future, whether installed or not and whether now lying loose or in case or which are now lying or stored in or about or shall hereafter from time to time during the continuance of the security of these present be brought into or upon or be stored or be in or about all the borrowers factories, premises and godwons situated at Transasia House, Plat No.N-8, Chandivali Studio Road, Andheri (E) Mumbai – 400072 and 47/6, Gelwad Falia Dhabel, Nani Daman – 396210. or wherever else the same may be or be held by any party to the order or disposition of the borrower or in the course of transit or on high seas or on order or delivery, howsoever and whosesoever in the possession of the borrower and entire by way of substitution or addition. |
|
4) Gist of the terms and conditions and extent and operation of the charge. |
In consideration
of ICICI having agred to lend and advance to the company the facility
agreement and declaration by the company, inter alia, as follows :- The said Goods
were thereby hypothecation to ICICI as and by way of first charge as security
for and be charged with the repayment of the facility with all interest liquidated
damages, commitment charged, premia on prepayment or on redemption, costs,
charged and expenses and all other monies payable by the company to ICICI in
respect there of. Provided that the charged of ICICI on the said Goods will
be subject to the charged or charges created and / or to be created by the
company :-
The company to duly repay to ICICI at Mumbai
the facility with interest and other monies as mentioned above payable by the
company to ICICI in respect thereof.
The Company to
keep the said goods in marketable and good condition and also insured as
provided therein. Power of entry,
power to take charge and/or possession, seize, recover, receive, appoint
receiver of and remove and/or sell by public auction or private contract,
dispatch for realization or otherwise dispose of or deal with all or any part
of the said goods etc. as provided therein. |
|
5) Name and Address and description of the person entitled to the charge. |
ICICI Limited ICICI Towers,
Bandra Kurla Complex, Bandra (E), Mumbai – 400051, Maharashtra, India |
|
6) Date and brief description of instrument modifying the charge |
Nil |
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
Nil |
Website details:
- Company Profile
:
Subject designs, manufactures and offers globally competitive healthcare
products and services to serve the global community through sustained
profitability and growth.
They offer their valued customers innovative products and services
with world class quality, reliability and high level of integrity .
They operate with utmost concern, strong commitment and mutual respect
towards their colleagues, associates and customers.
They strive to continuously improve and develop their people, products
and services through challenging career opportunities and extensive research
and development.
- R and D:
Subject recognizes R&D as the prime driver of innovation and
leadership and strives to be the top ten diagnostic players in the world.
Subject young and enthusiastic team of experts in software, mechanical
engineering, electronics and embedded software and Bio-chemistry has built an
impressive track record of successful projects. The Research and Development
department, a team of 70 research and development engineers, constantly work to
bring out products with appropriate technology and features to meet the
changing customer needs.
- Manufacturing Setup:
Subject Manufactures entire range of
Clinical Chemistry Analysers, Elisa Readers and Microplates.
These instruments manufactured, meet stringent quality
requirements and demands of the customers across the country and 54 countries around
the world. Subject has 3 state of the art manufacturing units at Daman, Speez
and Baddi. These units are ISO 9001:2000 certified.
- Quality Control Check :
They do extensive checks on all
components and processed parts at all stages. Accuracy of patient
data is ensured through extensive calibrator and control runs on each assembled
instrument prior to its release for distribution.
- Manufacturing Units:
Unit 1:
47/6, Gelwad Falia, Dhabhel, Nani
Daman-396210.
Unit 2:
B/11, OIDC Ringanwada, Nani Daman-396210
Unit 3:
SDF-VI, Unit No. 162, SEEPZ,
Andheri (East), Mumbai-400096
Unit 4:
SDF-VI, Unit No. 161, SEEPZ,
Andheri(East), Mumbai-400096
Unit 5:
Khasra Nos. 542,543,544 and 545
Village Malpur, Dist: Solan, H.P. Badddi-173205
Founder:
Mr. Suresh Vazirani, an Electrical Engineer from Nagpur University was
undergoing a Management training programme at a large Multinational company. He
abandoned this promising career, to join a social cause spearheaded by MRA
(Moral Re-armament) for creating awareness amongst the youth for the need to
build a great India - "A Clean, Strong and United India based on Secular
Moral Principles".
Mr. Suresh Vazirani, who grew up in the scenario landscaped by the
struggle and strife of the partition in India, worked honorary with this
movement for eight years. In this period he traveled extensively throughout
India, and other Asian Countries, meeting people from different walks of life,
as varied as peasants and Prime ministers.
In 1979, at the age of 29, he started his business with a capital of
Rs.250 Millions, the last honorarium from MRA. His enthused capabilities kept
him searching for new ways to contribute to society. With a broad vision to
serve Medical Community in the Indian Subcontinent, he marched single handedly
with a novel idea of marketing and servicing of Bio-medical equipments. His
individual efforts reaped the real fruits to his mission and the foundation
stone for subject was carved in 1985. He has been the guiding force for subject
and the Diagnostic community in India.
Alliances:
- Sysmex Corporation – Japan
Sysmex, whose principal activities are to develop, manufacture, market and sell clinical laboratory testing instruments to analyze cell and proteins contained in blood and urine is globally renowned for manufacturing Japan's first automated blood cell counter. Sysmex is also known for its "particle measuring technologies" and utilizing technologies to develop a variety of reagents, which are essential for inspections and tests. They also utilize technologies of systematization, which fully integrate robotics, information technology, and more in order to bring innovations to the sites of actual inspections. Integration of those various technologies is the driving force behind Sysmex's business activities.
- Medica - USA
Medica is known for being actively
engaged in the development of new technology on which the company will base
future analyzers with these same characteristics. The Company's rapid growth is
a result of strategic focus on the worldwide need to lower healthcare costs.
Medica uses its proprietary knowledge of ion-selective electrodes and
analytical microchemistry to manufacture a line of easy-to-use,
easy-to-maintain, and low-cost blood testing analyzers.
- Grifols – Spain
Grifols is a group of companies,
which serves healthcare professionals and patients in over 70 countries around
the world. They are known for research, development, manufacturing and
marketing of plasma derivatives, IV therapy, enteral nutrition, diagnostic
systems and medical materials. Grifols includes 26 companies from around the
world in the health sector which are divided into two main activities-
Industrial area and Commercial area. The industrial area includes all the
companies dedicated to developing, researching and manufacturing products and
services while the commercial area is dedicated to marketing, distribution and
providing customer service around the world from companies located in different
regions of the world.
- Diesse – Italy
Diesse Diagnostica Senese S.p.A.
is recognised as world-class manufacturer of innovative instrument systems and
reagents for infectious disease testing. Located in Siena, Italy and also known
for combining advanced technologies, enduring commitment to high quality standards,
Diesse has developed products which satisfy the growing demand for simplicity
and efficiency in each clinical laboratory.
- Biohit – Finland
Biohit, a global company operating all over the world, develops, manufactures and markets liquid handling products and accessories as well as diagnostic test systems for use in research, health care and industrial laboratories. In the diagnostics business, Biohit focuses on the research, development, production, and marketing of products (e.g. GastroPanel, Quick Tests) for the screening, prevention, and diagnosis of diseases of the gastrointestinal tract. Its production plants are located in Finland and China, sales and marketing subsidiaries are located in France, Germany, China, Japan, Russia, the U.K. and the U.S.
- Wako – Japan
Wako Chemicals USA, Inc. a wholly owned subsidiary of Wako Pure Chemical Industries Limited. of Japan. Wako Pure Chemicals Industries Limited worldly renowned for its high purity chemicals, established Wako Chemicals USA, Inc. to expand its presence in the United States. The first US operations opened in 1981.
- Fujirebio Diagnostics, Inc.
Can Ag, which is now bought over by Fujirebio Diagnostics, is a worldwide provider of tumor marker reagents and is known for being firmly committed to the development of innovative tumor marker tests within the area of oncology diagnostics. The company is based on the core competence in establishment and characterization of monoclonal antibodies, develops manufactures and market products in improving diagnosis and management of patients with severe diseases. The clinical focus areas are related to cancer diagnosis and determination of Biochemical Markers of Brain Damage.
- Awards:
Transasia,
India's First and Only Diagnostic Company to export sophisticated computerised
Blood Analysers and Reagents to over 30 countries world wide, receives the
"National Export Award" presented by Hon. Prime Minister of India
Shri. Atal Bihari Vajpayee.
A treasured moment in the eventful history of Transasia
topped the pinnacle of glory on the 8th of May 2000. The Hon. Prime Minister of
India Shri. Atal Bihari Vajpayee presented the Certificate of Merit to the
proud and nostalgic Mr. Suresh Vazirani-CMD TRANSASIA BIO-MEDICALS at Vigyan
Bhavan, New Delhi. Transasia was one among the 35 Indian exporters to be
awarded at the 32nd year of the National Export Awards, Organised by FIEO.
The award is a recognition of its excellent record export
performance of a compound growth rate of 7263.03% during the last two years and
392.86% growth during the last year. The tentacles of trade have penetrated in
the markets of HongKong, Germany, Zimbawe, Taiwan, Russia, Turkey and Spain.
Pursuing ever-higher levels of exports, especially in it's
most difficult year; braving stiff global competition was by no means an easy
task. The award put to test Transasia's abilities to meet the unrelenting
standards of overseas buyers to keep pace with the basic impulse of the
overseas markets.
Transasia by its export expansion has amply demonstrated
that Indian's are Achiever's in the competitive world. It will spare no effort
in achieving atleast 20 percent sustained growth in Indian exports.
Mrs. Mala Vazirani - Director, Transasia Bio-Medicals Ltd.
receives the "National Quality Award" presented by Hon. Prime
Minister of India Shri. Atal Bihari Vajpayee.
A short
span of 4 months, and Transasia was back again at Vigyan Bhavan on August 30th,
2000 to be felicitated at the first National Conference on Small Scale
Industries. At this momentous occasion, the Prime Minister of India, Mr. A. B.
Vajpayee reaffirmed his commitment to every SSI entrepreneur.
Transasia's
Quality progress, growth and efforts were recognised, by the Ministry of SSI
and ARI. The prestigious 'National Quality Award' was received by Mrs. Mala
Vazirani - Director, Transasia Bio-Medicals from Shri. A.B. Vajpayee. The
aggressive and industrious Smt. Vasundhara Raje, Minister of State - SSI and
ARI in her welcome address, expressed the need for reorienting operational
strategies, building institutional strengths, and bringing in efficiency and
quality standardisation to empower the sector.
The
trophy, speaks of Transasia's Quality Attitude in manufacturing world class
Diagnostic Products.
Transasia bags “Niryat Shree” awards for two consecutive
years
Our Chairman and Managing
Director, Mr. Suresh Vazirani and the Executive Director Mrs. Mala S Vazirani
received the coveted FIEO
(Federation of Indian Export
Organizations, set-up by Ministry Of Commerce, Govt. of India) Awards for 2
consecutive years at the Awards function held on December 26th, 2006 at Hotel
Shangri-La, New Delhi.
Transasia
receives the Award for the Most promising SME-Emerging India Awards(2005)
It was a proud moment for Transasia to be the recipient of the emerging India
award for the most promising SME in 2005. The award is recognition for the
steady progress and growth that Transasia has been achieving since its
inception.
National R&D Award 2005
The
R&D Center at Transasia has always been a matter of great pride to our
engineers and software professionals and awards like the National R and D award
for the best R and D development activities helps us strive for even more.
- Certifications :
ISO 9001:2000
Certification
Subject has always stood for quality and brings to its
Customers a range of quality products and solutions from its ISO certified
manufacturing units.
The TUV Rheinland/Berlin-Brandenburg Group of companies,
Germany certified subject with ISO 9001:2000 Certification.
It's endevour to bring quality products continue at various
levels as per the requirement and defined periodicity wherever applicable.
Sales
and Service :
Subject is India's No.1 Diagnostic Instrumentation Company
with over 10,000 installations to its credit and the largest field force
operating from 49 cities throughout the country, Transasia offers the best
after sales support. A strong team of 102 service engineers all over India
ensure maximum uptime and optimum use of all subject installations.
- North Zone
New Delhi
501, Prabhat Kiran, 17, Rajendra Place,
New Delhi-110008
Tel: 011-25732223
Fax: 011-25785451
Lucknow
B-33, Sector-K,, Aliganj,
Lucknow-22602 4
Tel : 052-23231778
Fax : 0522 4430900
Chandigarh
SCO 95, 1st Floor, Sector 44 C,
Chandigarh: 160044
Telefax: 017-24643837
Jaipur
House No. 453, Near Bees
Dukan, Adarsh Nagar,
Jaipur--302004 Tel.:0141-3232942
- East Zone
Kolkata
518, Kamalalaya Centre, 156A,
Lenin Sarani, Kolkata-700013
Tel: 033-22153898/22157839
Fax: 033-22158035
- West Zone :
Mumbai
8 Chandivali Studio Road, Andheri (E),
Mumbai - 400 072
Tel.: 022-40309000,
Fax: 022-2857 3030
Pune
AIBCN, Savarkar Udyog Bhavan,
Besides Balgandharv, Shivaji Nagar,
Pune-411005
Ahmedabad
116, Anand Mangal-III, Near
Municipal School, Ellise Bridge,
Ah`medabad-380006
Tel: 079-26407040/50
Fax: 079-26407030
- South Zone
Bengalooru
1st Floor, 15 Wood Street,
Richmond Road, Bengalaru-560025
Tel: 080-25568044
Fax: 080-25361387
Chennai
Flat No. 3/5, 1st Floor, Raghupriya
Apartments, 3, Krishnama Road
Nungam bakkam, Chennai-600034
Tel:044-28260310/28227149
Fax: 044-28259435
Hyderabad
1-10-27/1, 1st Floor,
Street 3, Ashok
Nagar,
Hyderabad-500020
Tel: 040-32949004
Kochi
36, 292/B, Vattakattuserry Buildings,
Lissie Pullepady road, Cochin-682018
Tel: 048-43205540
- Export
Subject continues to expand its
global marketing and service networks.
A worldwide network of distributors spread over 54 countries globally, not only
delivers products and detailed technical information, but assures instrument
maintenance, enabling optimum analyzer performance and good working orders at
all times.
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.39.36 |
|
UK Pound |
1 |
Rs.78.29 |
|
Euro |
1 |
Rs.58.48 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
7 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILIRY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
63 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|